ŌNŌ Retrieval Device Highlighted in 17 Presentations at New York Valves, June 2026!

Founded With Purpose

About Us

ŌNŌCOR Vascular was founded on a straightforward premise: device complications in the cath lab should not require open-heart surgery.

Designed From Experience

Born out of firsthand clinical experience with the limitations of conventional snare retrieval, the company was built by interventional cardiologists and cardiovascular surgeons who understood the problem from both sides of the table. The result is the ŌNŌ Retrieval System — an FDA 510(k)-cleared catheter-based device that gives physicians a reliable, percutaneous option when a cardiac implant migrates, embolizes, or fails to seat correctly.

Meet the Experts

Headshot of Matthew Gillespie

Matthew J. Gillespie, M.D.

Co-Founder

Dr. Matthew J. Gillespie is a renowned interventional cardiologist, innovator, and co-founder of ŌNŌCOR Vascular. Throughout his career, he has been dedicated to advancing minimally invasive cardiovascular therapies and developing technologies that improve procedural safety and patient outcomes.

Headshot of Mark Piper

Mark Piper

Co-Founder, Chief Executive Officer

Mark Piper is the Co-Founder and Chief Executive Officer of ŌNŌCOR Vascular, where he leads the company’s strategic direction, commercialization efforts, and operational growth. He brings extensive experience in the medical device industry, with a focus on bringing innovative cardiovascular technologies from development to market.

Headshot of Robert Gorman

Robert C. Gorman, M.D.

Co-Founder

Dr. Robert C. Gorman is a cardiac surgeon, researcher, and co-founder of ŌNŌCOR Vascular. His career has focused on advancing cardiovascular surgery through innovative device development, translational research, and the application of engineering to solve complex clinical problems.

Headshot of Joseph Gorman

Joseph H. Gorman III, M.D.

Co-Founder

Dr. Joseph H. Gorman III is a cardiac surgeon, inventor, and co-founder of ŌNŌCOR Vascular. His clinical and research career has centered on developing innovative technologies that improve the treatment of structural heart disease and support the continued evolution of minimally invasive cardiovascular therapies.